RZRezolute, Inc. RZLT · NASDAQ
$3.58 -8.21% (-$0.32)
- Market cap
- $375.5M
- Enterprise value
- $364.9M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -82.4%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.61
- Free float
- 63.0%
About the company
Rezolute, Inc. (RZLT) is a biotechnology company specializing in the development of therapeutics to improve the lives of patients suffering from metabolic disorders and endocrine disorders. Headquartered in the United States, the company focuses on researching and developing new treatment approaches and therapies for patients with type 1 diabetes and other health issues. The company concentrates on innovations in pharmacology and therapeutic methods, working to create new drugs that can enhance the quality of life for affected patients. Shares of Rezolute, Inc. (RZLT) can be an appealing choice for investors seeking investment opportunities in the biotechnology and healthcare research sector.
Sector
Healthcare
Industry
Biotechnology
CEO
Nevan Charles Elam
Employees
58
Headquarters
Redwood City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number